Hong Kong Department of Health Visited Sinovac on R&D and Production of H1N1 vaccine

2009-09-08

On the morning of September 8, 2009, the HK Department of Health delegation led by Dr PY LAM, Director of Health, Dr. Kwok-Yung Yuen, Honored Consultant, Dr.Anthony W.K.CHAN, Chief Pharmacist, and Dr Thomas TSANG, Controller, Centre for Health Protection, visited Sinovac for an inspection on R&D, production of H1N1 vaccine.

After listening to the introduction on H1N1 vaccine, the delegation also visited the production line, filling and packaging plant, quality control laboratory and checked the batch records of the H1N1 vaccine. The experts of the delegation appreciated Sinovac's research and production of H1N1 vaccine.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com